Friday, June 19, 2026
🇺🇸 FDA
ASCO 2026 pharmaceutical event banner
← Back to Events
Tier 1 Global Networking: High ONCOLOGY CONCLUDED

ASCO 2026 — McCormick Place, Chicago, United States

The 2026 ASCO Annual Meeting is The Place to Be. Learn more about the sessions, speakers, and science that will be presented at this year's meeting below. Answer who/what/when/where for ASCO 2026 Program pdf with verified dates, location, and what B2B readers should watch. ASCO 2

McCormick Place, Chicago, United States June 5 – June 9, 2026
45,000+ Attendees
9 Presentations
7 Companies
7 Drugs
All Events

Presentation data updated Jun 5, 2026, 9:21 AM UTC

Nova Event Impact Score
59 /100
  • Media coverage 10/20
  • Speaker quality 20/20
  • Pipeline relevance 2/20
  • Historical influence 13/20
  • Company participation 14/20

Key Takeaways

Key Themes

oncologycongressPipeline announcementsPartnership deals

Key Companies

Gilead SciencesAmgenMerck & Co.Johnson & JohnsonPfizer

Key Drugs

pembrolizumabsotorasibsacituzumab tirumotecanamivantamabpumitamig

Key Markets

US Americas

Key Opportunities

Partnership dealsLicensing discussionsVendor selection
Best for
Oncology BD teams Clinical development leaders Investors & analysts

amivantamab at ASCO 2026

2 presentations

amivantamabRybrevant, Lazcluze Drug profile linked when published in our directory.
ORAL Jun 5

Updated results from the open-label Phase I/Ib CHRYSALIS-2 study (NCT04077463) of amivantamab and lazertinib in non-small cell lung cancer

Johnson & Johnson$JNJ amivantamab(Rybrevant, Lazcluze) Phase I Non-small cell lung cancer NCT04077463
Event presentation hub → Company at this event →
INVESTOR IMPACT: ★★★★☆ 4/5
ORAL

Data for amivantamab in lung cancer

Johnson & Johnson$JNJ amivantamab non-small cell lung cancer
Event presentation hub → Company at this event →
INVESTOR IMPACT: ★★☆☆☆ 2/5